Financials data is unavailable for this security.
View more
Year on year Virax Biolabs Group Ltd had net income fall 23.38% from a loss of 5.46m to a larger loss of 6.73m despite a 1,727.34% increase in revenues from 8.56k to 156.42k.
Gross margin | 32.34% |
---|---|
Net profit margin | -4,308.35% |
Operating margin | -4,153.22% |
Return on assets | -88.11% |
---|---|
Return on equity | -92.92% |
Return on investment | -91.88% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Virax Biolabs Group Ltd fell by 5.76m. Cash Flow from Financing totalled 1.65m or 1,053.68% of revenues. In addition the company used 6.25m for operations while cash used for investing totalled 1.16m.
Cash flow per share | -3.31 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.09 |
---|---|
Tangible book value per share | 2.09 |
More ▼
Balance sheet in USDView more
Current ratio | 25.94 |
---|---|
Quick ratio | 25.58 |
Total debt/total equity | 0.0418 |
---|---|
Total debt/total capital | 0.0418 |
More ▼